Talk:Influenza vaccine: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 07:37, 2 May 2020 edit50.201.195.170 (talk) →Request edit - 6 of 7 M-001 trials completed. Only one of the 7 trials has results. None that BiondVax sponsored do.: new section← Previous edit		Latest revision as of 13:54, 10 January 2024 edit undoCewbot (talk \| contribs)Bots7,707,087 editsm Maintain {{WPBS}} and vital articles: 3 WikiProject templates. Merge {{VA}} into {{WPBS}}. Keep majority rating "B" in {{WPBS}}. Remove 3 same ratings as {{WPBS}} in {{WikiProject Viruses}}, {{WikiProject Medicine}}, {{WikiProject Pharmacology}}.
(18 intermediate revisions by 14 users not shown)
Line 1:		Line 1:
			{{copied\|from=Influenza vaccine\|to=Universal flu vaccine}}
	{{Vital article\|topic=Biology\|subpage=Health\|level=5\|class=B}}
⚫	{{Reliable sources for medical articles}}
	{{Talk header}}		{{Talk header}}
		⚫	{{COI editnotice}}
	{{ArticleHistory		{{ArticleHistory
	\|action1=GAN		\|action1=GAN
Line 11:		Line 11:
	\|topic=natsci		\|topic=natsci
	}}		}}
		⚫	{{WikiProject banner shell\|class=B\|vital=yes\|1=
		⚫	{{WikiProject Viruses\|importance=Top}}
		⚫	{{WikiProject Medicine\|importance=mid\|translation=yes\|translation-imp=high}}
			{{WikiProject Pharmacology\|importance=mid}}
		⚫	}}
		⚫	{{Reliable sources for medical articles}}

	{{User:MiszaBot/config		{{User:MiszaBot/config
	\|archiveheader = {{aan}}		\|archiveheader = {{aan}}
Line 19:		Line 26:
	\|archive = Talk:Influenza vaccine/Archive %(counter)d		\|archive = Talk:Influenza vaccine/Archive %(counter)d
	}}		}}

	{{WikiProjectBannerShell\|1=
⚫	{{WikiProject ~~Viruses~~\|class=B\|~~importance~~=~~Top}}~~
⚫	{{WikiProject Medicine~~\|class=B~~\|importance=mid\|translation=yes\|translation-imp=high}}
⚫	{{WikiProject ~~Pharmacology\|class=B~~\|importance=~~mid~~}}
⚫	}}
	{{Connected contributor (paid)		{{Connected contributor (paid)
	\| User1 = WanderingJosh \| U1-employer = BiondVax Pharmaceuticals \| U1-client = \| U1-EH = yes \| U1-banned = \| U1-otherlinks = COI declared		\| User1 = WanderingJosh \| U1-employer = BiondVax Pharmaceuticals \| U1-client = \| U1-EH = yes \| U1-banned = \| U1-otherlinks = COI declared
Line 36:		Line 39:
	\| User10 = \| U10-employer = \| U10-client = \| U10-EH = \| U10-banned = \| U10-otherlinks =		\| User10 = \| U10-employer = \| U10-client = \| U10-EH = \| U10-banned = \| U10-otherlinks =
	}}		}}
⚫	{{COI editnotice}}
⚫	~~{{dashboard~~.~~wikiedu.org~~ ~~assignment~~ \| course = Misplaced Pages:Wiki_Ed/University_Of_Cincinnati/Environmental_Public_Health_(Spring_Term) \| ~~assignments~~ = ] \| reviewers = ] }}

			==Wiki Education Foundation-supported course assignment==
		⚫	] This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available ]. Student editor(s): ]. Peer reviewers: ].

			{{small\|Above undated message substituted from ] by ] (]) 00:30, 17 January 2022 (UTC)}}
	== Should include the strongly significant relationship between drop in healthcare worker vaccination and rise in nosocomial influenza-like illness in their elderly patients ==		== Should include the strongly significant relationship between drop in healthcare worker vaccination and rise in nosocomial influenza-like illness in their elderly patients ==

Line 54:		Line 58:
	DOI: 10.1016/j.jhin.2014.01.005		DOI: 10.1016/j.jhin.2014.01.005

			== reformulation ==
	== merge proposal for specific vaccines ==

	See ] for a proposal to merge Influvac, Optaflu, Fluzone together into ] (and make it easy to add other specific brands such as ] as separate sections rather than redirects or new articles). Please centralise discussion over there. ] (]) 22:08, 5 December 2019 (UTC)

	== Oral Influenza Vaccine in Trials ==

	{{u\|Daniel.Cardenas}}, this is not considered a secondary source as defined in ] and is not suitable for inclusion. It's too early to include this. Numerous promising treatments in the clinical trial phase do not pan out. If it were phase III and in a prominent journal (e.g., New England Journal of Medicine), I could perhaps understand the rationale for including it (perhaps in a Research section). When you say it's being covered in a secondary source-do you have a well-respected peer-reviewed review journal article that covers this specific oral influenza vaccine? Or a tertiary reference like a textbook? This seems like you are ] the material in and not being respectful of ]-why? (yes, I know it's optional but it really is the accepted guidance on Misplaced Pages for the right thing to do-this is well-established).

	Additionally, what is discussed in the lead should also be covered in the body of the article and should be highly noteworthy (this is not yet noteworthy enough to merit inclusion in the lead-as above, it's premature at this time since many experimental treatments in phase II clinical trials fail). I will see what the community thinks for broader consensus and further discussion. ] (]) 18:37, 26 January 2020 (UTC)
	:I'm not sure I agree, but I'll remove it anyways. Thanks for the thorough explanation. ] (]) 18:48, 26 January 2020 (UTC)
	::If not, you're welcome to explain why it belongs. Otherwise, it should be removed. ] (]) 18:56, 26 January 2020 (UTC)
	:::Is there a precedent for phase 2 working better than existing treatments and not launching? ] (]) 18:59, 26 January 2020 (UTC)
	::::No, phase 2 trials have a . If it survives additional, larger and much more expensive phase 2 trials, as a vaccine, it will need to clearly demonstrate safety and efficacy in tens of thousands of people with flu. Without a major pharma partner (none displayed, -- this was my error, as Janssen is a partner for the oral vaccine; see below), and with a , it does not appear Vaxart has the finances to take this project much further . --] (]) 19:13, 26 January 2020 (UTC)
	:::::'''Note:''' I missed mention of the Janssen partnership on developing the oral vaccine, shown in the table footnotes on It was also discussed in the --] (]) 03:54, 27 January 2020 (UTC)
	::If we included information about this, it would belong in the ==Research== section (not the lead), and it would be a pretty bland statement that says there's some research on flu vaccines that can be delivered as a pill. {{pmid\|31978354}} could be cited for that. MEDRS has a strong preference for secondary sources, although ] does permit primary sources under limited circumstances, as a temporary measure. Alternatively, and more usually, we could just wait a few months. It seems likely that this will get mentioned in a secondary source before long.
	::I also want to say that while a flu vaccine in pill form could be more pleasant for the patients who are currently getting a flu jab every year (e.g., me), a vaccine that could bypass the ] problem and had no risk of spreading bloodborne infections is an important area of research. ] (]) 21:41, 26 January 2020 (UTC)
	::: {{re\|WhatamIdoing}} Someone did try to put it in ==Research== and mentioning {{pmid\|31978354}}, but it was removed by ]. While I agree the removed edit sounds like advert but if we just paraphrase that edit and remove advert part... then I think it'll be OK. ] (]) 01:17, 27 January 2020 (UTC)
	::::Would go in the research section if anything. Would like to see a review on the topic not a press release. ] (] · ] · ]) 01:53, 27 January 2020 (UTC)
	::::: OK, i have included it on research section. other reviews on the topic is scarce at the moment (afterall the publication is issued few days ago), but will update it once further review available. ] (]) 02:56, 27 January 2020 (UTC)
	::::::There's a review from 2008 by someone from that company, but I haven't found much else at PubMed. Google Scholar has a few more hits. ] (]) 03:59, 27 January 2020 (UTC)

	== Remove quadrivalent flu in the research section ==

	IMO Research section is only for vaccine in research and development phase. Since quadrivalent flu vaccines (injection or nasal) are already in the market or already past research phase. Can we remove "Quadrivalent vaccines for seasonal flu' sub-section in the Research section? and move the content elsewhere in the article. ] (]) 01:07, 19 February 2020 (UTC)

	== Request edit - 6 of 7 M-001 trials completed. Only one of the 7 trials has results. None that BiondVax sponsored do. ==

	<!-- PLEASE READ: Please provide your requested edit after the {{request edit}} below in a roughly "replace X with Y" format. Explain the rationale behind the edit and provide reliable sources to support the proposed changes. At the end of the request, add four tildes "~~~~" and click "Save Page" or "Publish changes". -->

	{{request edit}}
	>"As of 2019, there were some ongoing clinical trials of the M-001 universal influenza vaccine candidate" needs updating.
	The trial NCT03058692 has results, and 5 of the other 6 have completed. NCT02691130: results failed NLM's limited QC review - twice. None of BiondVax's 6 completed trials have published results. NCT01419925: results also failed NLM's limited QC review - three times. BiondVax's failed to submit the legally required "basic results" for a single one of its M-001 trials.

	This could be, and '''I ask it be noted with''', "As of May, 6 of 7 M-001 trials are completed. One of the 7 trials has results. None that BiondVax sponsored do."

			The reformulation section is getting a bit long, and should likely be moved to ].
	As for NCT03058692, the results are new, very long (about 67 p-values) and there's no summary or conclusion; I'm not sure what edit ''about that'' is appropriate. Expert help needed.--] (]) 07:37, 2 May 2020 (UTC)
			Also the 2022 sourthern hemisphere formulation is here: https://surv.esr.cri.nz/PDF_surveillance/Virology/FluVac/FluVac2022.pdf
			--] (]) 21:53, 15 February 2022 (UTC)

Latest revision as of 13:54, 10 January 2024

Text and/or other creative content from Influenza vaccine was copied or moved into Universal flu vaccine. The former page's history now serves to provide attribution for that content in the latter page, and it must not be deleted as long as the latter page exists.

This is the talk page for discussing improvements to the Influenza vaccine article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Misplaced Pages? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1, 2, 3Auto-archiving period: 3 months

Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Misplaced Pages:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent.

Influenza vaccine was a Natural sciences good articles nominee, but did not meet the good article criteria at the time. There may be suggestions below for improving the article. Once these issues have been addressed, the article can be renominated. Editors may also seek a reassessment of the decision if they believe there was a mistake.

Article milestones
Date	Process	Result
September 4, 2008	Good article nominee	Not listed

This

level-5 vital article is rated B-class on Misplaced Pages's content assessment scale.
It is of interest to the following WikiProjects:

Viruses Top‑importance

	Viruses portal This article is within the scope of WikiProject Viruses, a collaborative effort to improve the coverage of viruses on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.VirusesWikipedia:WikiProject VirusesTemplate:WikiProject Virusesvirus
Top	This article has been rated as Top-importance on the project's importance scale.

Medicine: Translation Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Misplaced Pages talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Translation task force (assessed as High-importance).

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Misplaced Pages's health content are defined in the guideline Misplaced Pages:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Influenza vaccine.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

WanderingJosh (talk · contribs) has been paid by BiondVax Pharmaceuticals. Their editing has included contributions to this article. COI declared here

Wiki Education Foundation-supported course assignment

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Jogabonito314. Peer reviewers: Jogabonito314.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 00:30, 17 January 2022 (UTC)

Should include the strongly significant relationship between drop in healthcare worker vaccination and rise in nosocomial influenza-like illness in their elderly patients

A 2014 study of 62,343 hospitalized patients found that their risk of infection with an influenza-like illness while in hospital rose over five-fold, from 1.1% to 5.7% (P < 0.001) as rates of influenza vaccination among their healthcare workers dropped by about 76%, from 13.2% to 3.1% (P < 0.001).

J Hosp Infect. 2014 Mar;86(3):182-7. doi: 10.1016/j.jhin.2014.01.005. Epub 2014 Feb 6.

Can influenza vaccination coverage among healthcare workers influence the risk of nosocomial influenza-like illness in hospitalized patients?

Amodio E1, Restivo V2, Firenze A2, Mammina C2, Tramuto F2, Vitale F2.

PMID: 24581755

DOI: 10.1016/j.jhin.2014.01.005

reformulation

The reformulation section is getting a bit long, and should likely be moved to Historical_annual_reformulations_of_the_influenza_vaccine. Also the 2022 sourthern hemisphere formulation is here: https://surv.esr.cri.nz/PDF_surveillance/Virology/FluVac/FluVac2022.pdf --Onco p53 (talk) 21:53, 15 February 2022 (UTC)

Categories: